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The sequestration of drugs away from cellular target
sites into cytoplasmic organelles of multidrug-resistant
(MDR) cancer cells has been recently shown to be a
cause for ineffective drug therapy. This process is
poorly understood despite the fact that it has been ob-
served in a large number of MDR cancer cell lines. Anal-
ysis of drug sequestration in these cells has traditionally
been done using fluorescent anthracycline antibiotics
(i.e. daunorubicin, doxorubicin). This narrow selection
of substrates has resulted in a limited understanding of
sequestration mechanisms and the intracellular com-
partments that are involved. To better characterize this
phenotype, we chose to examine the sequestration of
molecules having different acid/base properties in the
MDR HL-60 human leukemic cell line. Here we show
that weakly basic drug daunorubicin is sequestered into
lysosomes according to a pH partitioning type mecha-
nism, whereas sulforhodamime 101, a zwitterionic mol-
ecule, is sequestered into the Golgi apparatus through a
drug transporter-mediated process. Quantitative intra-
cellular pH measurements reveal that the lysosome-to-
cytosol pH gradient is expanded in the MDR line. More-
over, the MDR cells overexpress the multidrug
resistance-related protein (MRP1), which is localized to
the Golgi apparatus. These results demonstrate, for the
first time, that two distinct mechanisms for intracellu-
lar compartmentalization are operational in a single
MDR cell line.
The resistance of tumor cells to anticancer agents remains a
major cause of treatment failure in patients with cancer. MDR1
is a term used to describe a resistance phenotype in which cells
become simultaneously resistant to different drugs with no
obvious structural similarities or mechanisms of action (1). The
emergence of MDR is multifactorial. Decreased drug accumu-
lation and/or increased efflux, increased detoxification, in-
creased DNA repair, and altered cell cycle regulation have all
been implicated (2). Interestingly, many MDR cell lines have
demonstrated the capacity to compartmentalize drugs away
from intracellular target sites (3). In drug-sensitive cell lines,
chemotherapeutic agents are localized to a significant extent
within the cell nucleus. In contrast, the MDR cells compart-
mentalize drug within distinct cytoplasmic organelles. This
sequestration serves to protect the MDR cell from the cytotoxic
effects of drugs since cellular targets are often associated with
the nucleus.
There are at least two mechanistic explanations that can be
used to rationalize the exaggerated drug sequestration capac-
ity of subcellular compartments contained within MDR cancer
cells (3). The first involves members of the ATP binding cas-
sette superfamily of transporter proteins such as P-glycopro-
tein (P-gp) and the multidrug resistance-related protein 1
(MRP1). The overexpression of these transporter proteins in
MDR cell lines is well known, and they are traditionally
thought to participate in drug efflux at the plasma membrane
(4). Recent evidence suggests that these transporters may also
drive sequestration into organelles (5).
Immunofluorescence studies have demonstrated that a num-
ber of different ATP binding cassette transporters are localized
to intracellular compartments in MDR cell lines (6–11). How-
ever, some controversy exists as to whether or not the observed
intracellular localization of these proteins is a normal compo-
nent of their biosynthesis, processing, and transport from the
endoplasmic reticulum to the plasma membrane. Nevertheless,
when these proteins are expressed at the plasma membrane,
they have been shown to be involved in the transport of a wide
range of substrates including weakly acidic, neutral, and basic
compounds (12).
For weakly basic drugs, the accumulation in sequestering
organelles can be explained by alterations in intracellular pH
gradients. The lumenal pH of lysosomes has been shown to be
considerably lower in MDR cells, resulting in an enhanced
lysosome-to-cytosol pH differential (3, 13). This can provide a
driving force for the accumulation of weakly basic compounds
into acidic organelles (2, 14–16). This phenomenon also occurs
in normal non-transformed cells and is referred to as lysoso-
motropism (17). Lysosomotropic agents are characteristically
defined as weak bases with pKa near 7 and are membrane-
permeable in the non-ionized form but relatively impermeable
in the ionized form. At cytoplasmic pH (pH 7.2), a significant
fraction of these molecules will exist in the non-ionized form
and will readily permeate lipid bilayers of subcellular or-
ganelles. When these drugs diffuse into acidic compartments
such as lysosomes (pH 4–5), they become ionized to a greater
extent and less able to diffuse back through the lipid bilayer. In
transformation from a normal cell to a cancerous one, it has
been shown that the lumenal pH of lysosomes from the cancer
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cell is elevated by at least 1.5 pH units (16). Consequently, the
pH differential between the lysosomes and the cell cytosol is
reduced. This, in turn, results in decreased sequestration of
these compounds into the lysosomal compartment. In MDR
cancer cells, lysosomal acidification is thought to be re-estab-
lished (18). Thus, the lysosome-to-cytosol pH differential is
again expanded, which in turn provides the driving force for
the accumulation of weakly basic drugs. In summary, both
normal cells and MDR cancer cells have acidic lysosomes,
which can result in weak base sequestration. Alternatively,
drug-sensitive cancer cells have a significantly reduced seques-
tration capacity due to the less acidic nature of their lysosomal
compartment.
Previous reports on this topic have proposed either the in-
volvement of drug transporters or the involvement of a pH
partitioning type mechanism, but never both. We describe ex-
periments here that show, for the first time, that both of these
mechanisms are simultaneously operational in the MDR HL-60
human leukemic cell line. Daunorubicin, a weakly basic anti-
cancer drug, is sequestered into the lysosomal compartment via
a pH partitioning mechanism. The zwitterionic molecule, sul-
forhodamine 101 (SR101), is sequestered into the Golgi appa-
ratus through an MRP1-mediated pathway.
EXPERIMENTAL PROCEDURES
The human acute promyeloid leukemia cell line HL-60 and its doxo-
rubicin-selected resistant HL-60 ADR cell line were kindly provided by
Dr. Yueshang Zhang (Arizona Cancer Center, University of Arizona).
Cell lines were grown in RPMI 1640 medium supplemented with 10%
fetal calf serum, 10 mM Hepes, 1 mM sodium pyruvate, 0.1% penicillin,
0.1% streptomycin. Cells were maintained at a density of 1  105 to 1 
106 cells/ml at 37 °C in a humidified 5% CO2 atmosphere. Daunorubi-
cin, MK571, nigericin, monensin, concanamycin A, buthionine sulfoxi-
mine (BSO) were purchased from Sigma. Sulforhodamine 101, NBD-
C6-ceramide, FITC-dextran (molecular weight, 10,000), (5-and 6-)
carboxyl SNARF1 AM acetate ester, Lysotracker Green DND-26, and
Oregon Green were obtained from Molecular Probes (Eugene, OR).
Fluorescence Co-localization Experiments—Cells were grown to a
density of 1  106 cells/ml prior to experimentation. Lysotracker Green
or FITC-dextran was used to stain lysosomes. Lysotracker Green (100
nM) was incubated with cells for 1 h at 37 °C. FITC-dextran (5 mg/ml)
was incubated with cells for 30 min, which was followed by a 24-h
incubation in medium devoid of the dextran. To label the Golgi appa-
ratus, cells were incubated with NBD-C6-ceramidine (5 M) for 30 min.
Following incubation with probe/drug, cells were pelleted (1,000 rpm, 5
min) and washed twice with ice-cold PBS to remove unincorporated
compounds. Cells were viewed with a microscope (Leica Diaplan, Leitz
Weltzar, Germany) equipped for epifluorescence with a 100 objective,
and images were captured using an Orca ER camera (Hamamatsu
Corp.) controlled by SimplePCI imaging software (Compix Inc.). The
data were exported as 8-bit TIFF files and processed using Adobe
PhotoShop.
Immunofluorescence—Cells were fixed using 3.7% formaldehyde for
30 min at room temperature. Cells were permeabilized and blocked
using 0.05% saponin, 5% goat serum in PBS for 30 min. Primary and
secondary antibody incubations were in PBS containing 5% goat serum
and 0.05% saponin for 1 h. The primary rat monoclonal antibody for
MRP1 (MRPr1, Monosan Antibodies, Uden, The Netherlands) and the
primary mouse monoclonal antibodies to the trans-Golgi network-spe-
cific protein p230 and the lysosomal membrane protein LAMP-1 (BD
Transduction Laboratories) were all diluted 1:100. Following primary
antibody incubations, cells were washed four times with PBS contain-
ing 0.05% saponin. Secondary antibodies (FITC-labeled goat anti-rat
and TRITC-labeled goat anti-mouse, both from Sigma) were diluted
1:500. Cells were subsequently washed four times with PBS prior to
fluorescence microscopy.
Protein Expression in Cell Membranes—A post-nuclear supernatant
was prepared from 50  106 cells pelleted at 1000 rpm for 5 min and
washed twice with ice-cold PBS. The cell pellet was suspended in 1 ml
of hypotonic buffer containing 15 mM potassium chloride, 1.5 mM mag-
nesium acetate, 1 mM dithiothreitol, and 10 mM Hepes (pH 7.4) supple-
mented with 0.1 mM phenylmethylsulfonyl fluoride, 5 mg of DNase I,
and 1 g/ml each of aprotin, leupeptin, and pepstatin. Cells were
allowed to swell on ice for 10 min followed by 20 strokes with a Dounce
homogenizer (pestle B). Subsequently, 0.2 ml of a solution containing
375 mM potassium chloride, 22.5 mM magnesium acetate, 1 mM dithio-
threitol, and 220 mM Hepes at pH 7.4 was added. The homogenate was
centrifuged at 2,500 rpm at 4 °C for 10 min to pellet cell debris and
nuclei and to yield the post-nuclear supernatant. Total membrane pro-
tein was obtained by ultracentrifugation of the post-nuclear superna-
tant at 4 °C, 100,000  g for 1 h. The pellet was resuspended in 50 l
of PBS, and aliquots of this fraction containing 10 g of protein (accord-
ing to Bradford assay with bovine serum albumin standard) were re-
solved by 7.5% SDS-PAGE. After transfer to nitrocellulose, MRP1, P-gp,
and actin (control) were detected by Western blot analysis using the
anti-MRP1 monoclonal antibody MRPm6 (1:200), anti-P-gp monoclonal
antibody C219 (1:500), or anti-actin monoclonal antibody (1:500). MRP1
and P-gp antibodies were from Monosan Antibodies, and the actin
antibody was obtained from Sigma.
Cellular pH Measurements—Ratiometric pH-sensitive probes, FITC
dextran, and (5-and 6-) carboxyl SNARF1 AM acetate ester were used
to determine the pH within the lysosomes and cytosol, respectively.
Fluorescence measurements were made using a PerkinElmer Life Sci-
ences LS 50B spectrofluorometer. Intralysosomal pH was determined
using a slightly modified procedure of Altan et al. (16). Briefly, 107 cells
were incubated with 5 mg/ml FITC-dextran for 30 min. The cells were
then washed four times with RPMI 1640 medium (without phenol red)
and incubated in the same medium for 24 h in the cell culture incubator.
Cells were transferred to PBS, and the fluorescence emissions at 530
nm were measured at two excitation wavelengths, 490 and 450 nm,
respectively. The ratio of emission intensities was determined and
converted to pH using the previously referenced standard calibration
procedure. Cytosolic pH was determined using a slightly modified pro-
cedure of Belhoussine et al. (19). Briefly, 107 cells were incubated with
4 M (5-and 6-) carboxyl SNARF1 AM acetate ester for 1 h, washed
twice with PBS, and resuspended in PBS prewarmed to 37 °C. Fluores-
cence emission intensities at 580 and 640 nm were measured at an
excitation wavelength of 514 nm. The ratio of the emission intensities at
the two emission wavelengths was determined and converted to pH
using the referenced methodology.
Quantitative Assessment of Daunorubicin Total Cell Uptake—Cells
(107) were preincubated with 100 M BSO for 24 h followed by incuba-
tion with daunorubicin (2 M) for 1 h. Cells were pelleted (1000 rpm, 5
min) and washed twice with ice-cold PBS. The pellet was suspended in
0.75 ml of acetonitrile, vortexed for 10 s, and sonicated for 15 min. The
resulting suspension was centrifuged at 13,000 rpm for 10 min, and a
500-l portion of the supernatant was evaporated to dryness. The
residue was analyzed by HPLC following dissolution in 100 l of mobile
phase (30% acetonitrile, 70% 10 mM ammonium acetate, pH 8.2). The
HPLC system was comprised of a Waters 600E system controller, 616
pump, 717 plus autosampler and 474 fluorescence detector set at
470-nm excitation and 560-nm emission wavelengths (Waters Corp.,
MA). A C18 reversed phase X-terra column (Waters Corp.) was used for
analysis. Extraction efficiencies for daunorubicin from cells were deter-
mined by spiking in known amounts of drug (four in total, representing
low, medium, and high concentrations) into blank cell pellets and car-
rying out the previously described extraction procedure. The extraction
efficiency was found to be 48.2  2.7%. This standard curve was linear
and was subsequently used to calculate cellular drug accumulation
from experimental samples.
IC50 Evaluations—Cell sensitivity to daunorubicin was determined
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay as described by Mosmann (20). Briefly, cells were seeded in
quadruplicate on 96-well culture plates at a density of 1  104 cells/well
and were treated with selected concentrations of either daunorubicin or
SR101 and then incubated for a period of 3 days. At the end of the
incubation period, 10 l of a 5 mg/ml solution of MTT in PBS was added
to each well, and the plates were returned to the incubator for an
additional 4 h. A 100-l portion of Me2SO was added to each well, and
the absorbance was measured at a wavelength of 590 nm in a micro-
plate reader. For SR101, cell viability was determined using trypan
blue staining with a hemacytometer since the color of SR101 interfered
with the MTT assay. IC50 was defined as the concentration of drug
causing 50% inhibition of cell growth as compared with untreated
control.
RESULTS
Identification of Drug Sequestering Organelles—The model
compounds utilized in this study had suitable fluorescence
properties that allowed us to visualize their intracellular dis-
tribution in cells using a fluorescence microscope. We evalu-
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ated the intracellular distribution of daunorubicin, SR101, and
Oregon Green in the HL-60 ADR cell line and compared this
with the parental drug-sensitive cell line using identical incu-
bation conditions. The structures of these three compounds are
shown in Fig. 1. Fig. 2 shows that all three compounds dis-
played somewhat diffuse cellular fluorescence when incubated
with drug-sensitive HL-60 cells. In the HL-60 ADR cell line,
both daunorubicin and SR101 were sequestered into cytoplas-
mic organelles; the subcellular distribution of Oregon Green
was not significantly altered. In the MDR line, daunorubicin
consistently stained cytoplasmic vesicles throughout the cell
cytoplasm, whereas SR101 stained a more restricted perinu-
clear location. This difference prompted us to investigate the
identity of drug sequestering organelles. Direct co-localization
of daunorubicin and SR101 could not be achieved because of
significant overlap of the fluorescent properties for these two
molecules. We therefore sought to independently identify drug-
sequestering organelles using fluorescence co-localization ex-
periments with organelle-specific fluorescent probes and vital
stains. We found that daunorubicin co-localized with the lyso-
somal vital stain Lysotracker Green (Fig. 3A). Considering the
fact that lysosomal vital stains such as Lysotracker Green can
non-selectively stain additional organelles (21), we further
demonstrated the co-localization of daunorubicin with FITC-
dextran localized to lysosomes, which is a more specific stain
(Fig. 3B). The co-localization of daunorubicin with the FITC-
dextran further supports the involvement of lysosomes in the
sequestration of this compound. Unlike daunorubicin, SR101
was not co-localized with lysosomes (Fig. 4B). SR101 was found
to co-localize with NBD-C6 ceramide, a Golgi-specific vital stain
(Fig. 4A).
Mechanistic Evaluation of Drug Sequestration—We next
sought to obtain preliminary results with regard to relevant
mechanism(s) for these two compound-sequestering organelles.
We first examined the possibility that daunorubicin is seques-
tered into lysosomes via a pH partitioning mechanism. The
theoretical basis for the pH partitioning mechanism requires
the lysosome-to-cytosol pH differential to be greater in the
MDR line relative to the sensitive line. To test this, we meas-
ured the pH of the cytosol and lysosomes for both cell lines.
FITC-dextran was used to measure lysosomal pH, and (5-and
6-) carboxyl SNARF1 AM acetate ester was used to measure
cytosolic pH. Table I shows that the pH differential is 1.95 in
MDR cells but only 0.52 in sensitive cell lines, which is consist-
ent with the pH partitioning mechanism. To further evaluate
this, HL-60 ADR cells were preincubated with the proton iono-
phores nigericin and monensin, which abolish cellular endo-
membrane pH gradients (18). The distribution of daunorubicin
in the HL-60 ADR cells with and without pH gradient disrup-
tion is shown in Fig. 5. Cells with disrupted pH gradients were
no longer able to sequester daunorubicin into lysosomes, and
the cellular distribution now resembled the distribution in
drug-sensitive cells. Conversely, the localization of SR101 to
the Golgi apparatus was not noticeably affected by pH gradient
disruption. Immunofluorescence staining of the lysosomal
membrane protein LAMP-1 confirmed that cells with disrupted
pH gradients had lysosomal morphology similar to cells with-
out pH disruption (data not shown). This supports the idea that
daunorubicin is sequestered into lysosomes by a pH partition-
ing mechanism, whereas SR101 is sequestered into the Golgi
apparatus by an alternative mechanism. For SR101, we antic-
ipated the involvement of drug transporter proteins. We
screened for the expression of common drug transporter pro-
teins from whole cell homogenates from sensitive and MDR
lines using Western blot analysis (Fig. 6A). We found that
resistant cells showed a significant overexpression of the drug
transporter protein MRP1 in comparison with sensitive cell
lines, which had no detectable expression of this protein. We
also examined the distribution of the drug transporter P-gp and
found no detectable expression in either sensitive or resistant
cell lines (data not shown). The intracellular localization of
MRP1 in the HL-60 ADR cell was determined using an immu-
nofluorescence protocol. Cells were incubated with a rat mono-
clonal antibody against MRP1, which was then localized with a
FIG. 2. Both daunorubicin and SR101 are sequestered into
cytoplasmic compartments in the HL-60 ADR cells, a process
that does not seem to occur in drug-sensitive cells. The intracel-
lular distribution of Oregon Green does not change. Cells were incu-
bated with indicated compound for 1 h, washed, and visualized using
fluorescence microscopy using appropriate filter sets. The concentra-
tions of compounds used for incubations were 2, 5, and 5 M for dauno-
rubicin, SR101, and Oregon green, respectively.
FIG. 1. Structures of compounds used in this study. Daunorubicin is a weakly basic anticancer agent. SR101 and Oregon Green are
zwitterionic and weakly acidic fluorescent probes, respectively.
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FITC-labeled goat anti-rat secondary antibody (Fig. 6B, lower
panel). This micrograph suggested that MRP1 had a significant
degree of intracellular expression in addition to plasma mem-
brane localization. Immunofluorescence staining of the trans-
Golgi network with anti-p230 antibody in the same cell is
shown in the middle panel. The significant overlap of the
merged images is consistent with MRP1 presence in the Golgi
apparatus. To further demonstrate the role of MRP1 in the
sequestration SR101, HL-60 ADR cells were preincubated with
the MRP1 inhibitor MK571, and the effect on the intracellular
sequestration was evaluated. Fig. 7A shows that SR101 fails to
be significantly sequestered into the Golgi apparatus in the
presence of the MRP1 inhibitor. Contrary to this, the inhibitor
had no apparent effect on daunorubicin sequestration. This
finding suggests that MRP1 is involved in the sequestration of
SR101 in the Golgi apparatus. Moreover, the lack of effect of
MK571 on daunorubicin sequestration suggests that daunoru-
bicin sequestration is not mediated by MRP1. MRP1-mediated
transport of drugs is often associated with glutathione co-
transport or with a covalent coupling of the substrate to gluta-
FIG. 3. Lysosomes are involved in the sequestration of dauno-
rubicin in the HL-60 ADR cell line. Daunorubicin fluorescence mi-
crographs are shown on the left panels. Middle panels display the same
cells visualizing lysosomes stained with Lysotracker Green (A) and with
FITC dextran (B). Panels to the right represent the merged images.
Daunorubicin incubation conditions are described in the legend for Fig.
2. Lysostracker Green and FITC dextran incubation conditions are
described under “Experimental Procedures.”
FIG. 4. SR101 co-localizes with the Golgi apparatus and not
with lysosomes in the HL-60 ADR cell line. The left column shows
SR101 distribution. The middle column shows the fluorescent staining
of the Golgi apparatus with NBD-C6 ceramide (A) and of the lysosomes
with FITC dextran (B). The right column is the merge of these two
images. SR101 incubation conditions are described in the legend for Fig.
2. NBD-C6 ceramide incubation conditions are described under “Exper-
imental Procedures.”
TABLE I
Experimentally determined lysosomal and cytosolic pH values
for HL-60 cells
Values are the means of three determinations  S.E.
Cell line Lysosome pH Cytosol pH pHa
HL-60 6.44  0.17 6.96  0.17 0.52
HL-60 ADR 5.17  0.14 7.12  0.04 1.95





7.13  0.11 7.21  0.15 0.08
a Represents the lysosome to cytosol pH differential.
b Nigericin (10 M) and monensin (20 M) were incubated with cells in
PBS (pH 7.4) for 30 minutes at 37 °C.
c Concanamycin A (20 nM) was incubated with cells for 24 hours at
37 °C prior to pH determinations.
FIG. 5. Disruption of endomembrane pH gradients leads to
release of daunorubicin yet has no effect on the sequestration of
SR101 in the HL-60 ADR cell line. pH gradient disruption was
achieved by preincubating cells with nigericin (10 M) and monensin
(20 M) for 30 min prior to incubation with daunorubicin or SR101 (see
the legend for Fig. 2 for conditions).
FIG. 6. HL-60 ADR cells overexpress MRP1, which is localized
to the Golgi apparatus. A, Western blot for MRP1 and actin (control)
from membrane fractions isolated from HL-60 and HL-60 ADR cell
lines. MW, molecular weight. B, immunofluorescence co-localization of
MRP1 and the Golgi-specific protein p230 in the HL-60 ADR cell line.
See “Experimental Procedures” for details.
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thione prior to transport (22). Therefore, we evaluated the
effect of an inhibitor of cellular glutathione biosyntheses (BSO)
on the sequestration of SR101 in the Golgi apparatus. Like
MK571, BSO nearly abolished the sequestration capacity of the
Golgi apparatus for SR101 yet had no influence on daunorubi-
cin sequestration (Fig. 7B). The lack of effect of BSO on dauno-
rubicin sequestration in lysosomes is somewhat surprising
since there is evidence that suggests that the activity of vacu-
olar H ATPases may be inhibited by oxidation resulting from
glutathione depletion (23, 24). This does not appear to be the
case with HL-60 ADR cells under our experimental conditions
for BSO treatment. Lysosomal pH was not significantly per-
turbed (pH values of 5.34  0.08 and 5.15  0.12 in HL-60 ADR
cells with and without BSO treatment, respectively). We also
did not see any observable change in lysosome morphology with
BSO treatment. This was evaluated by comparisons of LAMP-1
immunofluorescence micrographs (data not shown). Neverthe-
less, this observation is consistent with the requirement of glu-
tathione in the MRP1-mediated transport of SR101 into the Golgi
apparatus. HPLC analysis of HL-60 ADR cell extracts revealed
only parent SR101; therefore, we think that this step is a gluta-
thione co-transport process rather than a covalent coupling.
DISCUSSION
In most cases, the intracellular distribution of drugs has
been evaluated in cultured cells using fluorescent drugs in
conjunction with fluorescence microscopy. The anthracycline
antibiotics (i.e. daunorubicin, doxorubicin) represent one of the
few classes of anticancer agents with suitable fluorescence
properties for such analysis. Consequently, most reports study-
ing this drug sequestration phenotype have focused on these
weakly basic anticancer drugs. This has led to significant
ambiguity regarding the underlying mechanism(s) that drive
sequestration because weak bases can be considered likely
candidates for drug transporter proteins as well as pH gradi-
ent-driven accumulation.
An important consideration that has not been considered
previously in the literature is the potential involvement of
multiple sequestration mechanisms within a given MDR can-
cer cell. These mechanisms could function concertedly within a
single organelle class, or they could act independently on dif-
ferent organelles. To investigate these possibilities, we evalu-
ated the sequestration capacity for a set of compounds with
different acid-base properties: daunorubicin (a weak base che-
motherapeutic agent), SR101 (a zwitterionic fluorescent mole-
cule), and Oregon Green (a weakly acidic fluorescent molecule).
Of these three molecules, only daunorubicin would be expected
to be sequestered into acidic cytoplasmic organelles via a pH-
partitioning mechanism. Conversely, considering the broad
substrate specificity of drug transporter proteins, all three
would be potential candidates for sequestration according to
transporter-mediated sequestration mechanism. This approach
allowed us to demonstrate that the HL60 ADR cell line has the
capacity to sequester different molecules according to different
mechanisms into distinct organelles. Our results suggest that
SR101 is sequestered into the Golgi apparatus by an MRP1-
mediated process, whereas daunorubicin is sequestered into ly-
sosomes according to a pH partitioning mechanism. In both
cases, this compartmentalization event can be correlated with
increased resistance to the sequestered compound. For daunoru-
bicin, the IC50 values in HL-60 and HL-60 ADR cells are 42  5
and 4196  99 nM, respectively; for SR101, these values are
415  94 and 1000  287 M, respectively. However, both se-
questration events correlated with increased resistance, the de-
gree of which appears to be most significant with daunorubicin.
This difference can most likely be attributed to different locations
and/or mechanisms of cellular toxicity for these two compounds.
Previous mechanistic explanations for daunorubicin seques-
tration in MDR cell lines have been contradictory. Reports have
proposed that a pH partitioning mechanism is responsible (16,
FIG. 8. Treatment of HL-60 ADR cells with BSO causes an
increase in the total cell accumulation of daunorubicin, which
results in a corresponding decrease in the daunorubicin IC50.
The columns on the left are untreated HL-60 ADR cells; those on the
right have been pretreated with BSO prior to daunorubicin incubation.
Data are the means of three experiments  S.E.
FIG. 7. The MRP1 inhibitor MK571 and the glutathione-deplet-
ing agent BSO disrupt the sequestration of SR101 but have no
effect on daunorubicin localization. In A, HL-60 ADR cells were
incubated with MK571 (100 M) for 1 h prior to daunorubicin and
SR101 incubation (see the legend for Fig. 2 for conditions). In B, HL-60
ADR cells were incubated with BSO (100 M) for 24 h prior to dauno-
rubicin and SR101 incubation. Note that BSO treatment significantly
enhanced daunorubicin accumulation (Fig. 8) and fluorescence inten-
sity. To assess daunorubicin localization patterns, fluorescence gain
settings were individually optimized for each of these micrographs.
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18, 25), yet others have suggested that drug transporters are
principally involved (26, 27). The former studies are consistent
with our findings in the HL-60 ADR cell line. We have demon-
strated the importance of the lysosome-to-cytosol pH gradient
in drug sequestration; however, this information alone does not
rule out the potential involvement of drug transporter proteins
since these proteins could be indirectly participating in drug
sequestration through intracellular pH modulation. ATP bind-
ing cassette transporters such as P-gp and MRP1 have been
shown to influence pH gradients across the plasma membrane
of cells (28, 29). Correspondingly, if these transporters are
localized to intracellular organelles, it is possible that these
transporters could cause acidification of the drug sequestering
organelles, if properly oriented. The exact mechanism for re-
acidification of lysosomes in MDR cells is not known at this
time. Normal regulation of organelle pH is carried out by vac-
uolar (H)-ATPases (V-ATPase) and associated ion channels to
dissipate membrane potential (30). Our data with HL-60 ADR
cells support the idea that lysosomal reacidification in HL-60
ADR cells is regulated by V-ATPase and not by MRP1. In
addition, our data suggest that MRP1 is not localized with
lysosomes, due to the lack of sequestration of SR101 with
daunorubicin in lysosomes (Fig. 4). We have also shown that
the specific V-ATPase inhibitor, concanamycin A (Table I), is
able to raise lysosomal pH from 5.17 to 7.13 in HL-60 ADR
cells, and this resulted in diminished lysosomal sequestration
capacity (data not shown), similar to that observed with the
proton ionophores shown in Fig. 5. These findings are consist-
ent with those of Ma and Center (31), who have shown that the
gene encoding the V-ATPase subunit C is overexpressed in
HL-60 ADR cells.
Contrary to our findings, studies have suggested that dauno-
rubicin is sequestered into cytoplasmic organelles of MDR
K562 and HL-60 cells according to an MRP1-mediated process
(26, 27). Confusion in this identification might be attributed to
the inability of the authors to directly co-localize drug trans-
porter with sequestered drug. This is because the permeabili-
zation steps required for immunofluorescence release seques-
tered compounds. We have circumvented this obstacle by co-
localizing MRP1 with the Golgi-associated membrane protein
P-230 and separately examining the co-localization of Golgi-
specific vital stain NBD-C6 ceramide with either daunorubicin
or SR101. We observed that SR101 was sequestered within the
Golgi in HL-60 ADR cells, whereas daunorubicin was not.
Studies implicating the involvement of MRP1 in the sequestra-
tion of daunorubicin arise from experimental observations us-
ing BSO to deplete cellular glutathione. As mentioned earlier,
glutathione is thought to be required for the transport of drugs
mediated by MRP1. When cells are treated with BSO, previous
authors have shown that cells are more sensitive to daunoru-
bicin and that nuclear concentrations of daunorubicin are in-
creased relative to untreated cells (26, 27). However, these
studies did not show that BSO was able to directly alter the
intracellular sequestration of daunorubicin. Our observations
suggest that BSO has no effect on daunorubicin sequestration
but indeed mediates the release of SR101 (Fig. 7B). We think
that the reason for increased nuclear concentrations and in-
creased sensitivity to daunorubicin is due to an increase in
total cell accumulation capacity for daunorubicin in BSO-
treated cells. To demonstrate this, we quantitatively evaluated
daunorubicin sensitivity and total cell accumulation in the
HL-60 ADR cell line in the presence or absence of BSO (Fig. 8).
In the presence of BSO, we observe an approximately 3-fold
increase in whole cell accumulation. We also observe a 3.5-fold
increase in sensitivity to daunorubicin, which is in very close
agreement with results seen with the 3.1-fold increase ob-
served by Benderra et al. (27). As a result, we think that the
increase in sensitivity and nuclear accumulation in the pres-
ence of BSO is not due to a redistribution of sequestered drug
from cytoplasmic organelles, but instead, is directly caused by
an overall increase in drug accumulation. Further investiga-
tions are required to understand the mechanistic basis for
BSO-mediated increase in total cellular accumulation of
daunorubicin in this cell line.
In summary, we have shown for the first time that a single
MDR cancer cell is capable of sequestering different compounds
with different acid/base properties into different organelles.
This work demonstrates that the sequestration phenotype as-
sociated with certain cancer cells is more complex than origi-
nally thought. Many important chemotherapeutic agents are
neither weakly basic nor fluorescent. This work may help to
rationalize their reduced effectiveness in MDR cancer cells.
Furthermore, this information could lead to rational selection/
design of new anticancer drugs with a reduced capacity for
sequestration. Likewise, specific inhibitors of protein function
described in this report may be evaluated as adjuvants in MDR
cancer treatment.
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